The recent approval in South Korea includes both complicated skin and skin structure infections (cSSSI) and right-sided infective endocarditis (SAB/RIE). Cubicin was previously approved in Taiwan (in November of 2006) for cSSSI caused by Gram positive bacteria.
US-based Cubist said that the approvals were received by the company’s marketing partners, Kuhnil Pharmaceutical Corp for South Korea and TTY BioPharm Company for Taiwan.